Annals of Nuclear Medicine

, Volume 12, Issue 6, pp 341–347 | Cite as

Predicting the effects on patients with dilated cardiomyopathy of β-blocker therapy, by using iodine-123 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) myocardial scintigraphy

  • Keiichiro Yoshinaga
  • Minoru Tahara
  • Hiroyuki Torii
  • Koichi Kihara
Original Article


We examined whether the iodine-123 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) myocardial scintigraphy was useful for predicting the treatment response to β-blocker in patients with dilated cardiomyopathy (DCM).

Sixteen patients with DCM were studied. BMIPP single photon emission computed tomography (SPECT) was performed before β-blocker therapy. The count ratio of the heart (H) to the upper mediastinum (M) (H/M ratio) was calculated. Several measurements including the BMIPP H/M ratio before the administration of metoprorol were retrospectively compared among the 10 “good responders” (showing improvement by at least one NYHA class or an increase in the ejection fraction of ≧0.10, 6 months after the start of the drug therapy) and the 6 “poor responders.” The bull’s eye map of BMIPP was divided into 17 areas. Each segmental score was analyzed quantitatively by means of a two-point scoring system (good uptake ≧67%, poor uptake < 67%). The total score was regarded as the uptake score.

The H/M ratio was significantly higher in the good responders than in the poor responders (2.41 ±0.24 vs. 1.86 ±0.17 p < 0.01). There were no significant differences between the two groups in any other variable data at entry.

The uptake score was also a good index for predicting the therapeutic effect. When a relative uptake of 67% or higher was scored as 1, uptake scores of 9 to 17 corresponded to good responses (sensitivity = 100%, specificity = 100%, accuracy = 100%, positive and negative predictive value = 100%).

Although the number of patients studied is small, our results suggest that BMIPP myocardial scintigraphy can predict the response to a β-blocker in patients with DCM.

Key words

dilated cardiomyopathy β-blocker therapy iodine-123 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of beta-adrenergic receptor blockade in congestive cardiomyopathy.Br Heart J 37: 1022–1036, 1975.PubMedCrossRefGoogle Scholar
  2. 2.
    Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long-term β-blockade in dilated cardiomyopathy.Circulation 80: 551–563, 1989.PubMedGoogle Scholar
  3. 3.
    Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy.Lancet 342: 1441–1446, 1993.PubMedCrossRefGoogle Scholar
  4. 4.
    CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure the cardiac insufficiency bisoprolol study (CIBIS).Circulation 90: 1765–1773, 1994.Google Scholar
  5. 5.
    Packer M, Bristow MR, Cohn JN, Colucci WD, Fowler MB, Edward BS, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.N Engl J Med 34: 1349–1355, 1996.CrossRefGoogle Scholar
  6. 6.
    Yamada T, Fukunami M, Ohmori M, Iwakura K, Kumagai K, Kondoh N, et al. Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? A Histologic Viewpoint.J Am Coll Cardiol 21: 628–633, 1993.PubMedGoogle Scholar
  7. 7.
    Waagstein FF. The role of β-blockers in dilated cardiomyopathy.Curr Opin Cardiol 10: 322–331, 1995.PubMedCrossRefGoogle Scholar
  8. 8.
    Knapp FK, Ambrose KR, Goodman MM. New radioiodinated methyl-branched fatty acids for cardiac studies.Eur J Nucl Med 12: S39-S44, 1986.PubMedGoogle Scholar
  9. 9.
    Fujibayashi Y, Yonekura Y, Takemura Y, Wada K, Matsumoto K, Tamaki N, et al. Myocardial accumulation of iodinated beta-methyl-branched fatty acid analogue, iodine-125-15-(p-iodophenyl)-3-(R,S) methyl pentadecanoic acid (BMIPP) in relation to ATP concentration.J Nucl Med 31: 1818–1822, 1990.PubMedGoogle Scholar
  10. 10.
    Ogata M. Myocardial uptake of125I-BMIPP in rats treated with adriamycin.KAKU IGAKU (Jpn J Nucl Med) 26: 69–76, 1989.Google Scholar
  11. 11.
    Yong-ih Kim, Sawada Y, Fujiwara G, Chiba H, Nishimura T. Therapeutic effect of co-enzyme Q10 on idiopathic dilated cardiomyopathy: assessment by iodine-123-labelled 15-(p-iodophenyl)-3-(R,S) methyl pentadecanoic acid myocardial single-photon emission tomography.Eur J Nucl Med 24: 629–634, 1997.Google Scholar
  12. 12.
    Nishimura T, Uehara T, Shimonagata T. Clinical experience of123I-BMIPP myocardial imaging for myocardial infarction and hypertrophic cardiomyopathy.Ann Nucl Med 7 (Suppl 2): 35–39, 1993.Google Scholar
  13. 13.
    Narita M, Kurihara T, Shimonagata T, Nagata S, Haze K. Fatty acid metabolism in patients with idiopathic dilated cardiomyopathy: Characteristics and prognostic implications.J Cardiol 25: 223–231, 1995.PubMedGoogle Scholar
  14. 14.
    Bennett SK, Fisher ML, Krichten C, Patten RD, Greenberg NL, Gottlieb SS. Ischemic cardiomyopathy treated with metoprolol: baseline heart rate predicts likelihood of increased ejection fraction (abstract).Circulation 88 (Suppl 1): 1–105, 1993.Google Scholar
  15. 15.
    Akanuma M, Ohsuzu F, Katsushika S, Handa S, Yoshikawa T, Kawamura Y. Early blood pressure response was predictive of long term beneficial effects of beta-blocker therapy in dilated cardiomyopathy (abstract).Circulation 88: I-346, 1993.Google Scholar
  16. 16.
    Eichhorn EJ, Heesch FCM, Risser RC, Marcoux L, Hatfield B. Predictors of systolic and diastolic improvement in patients with dilated cardiomyopathy treated with metoprolol.J Am Coll Cardiol 25: 154–162, 1995.PubMedCrossRefGoogle Scholar
  17. 17.
    Lechat P, Boissel JP, Nemoz C, Jaillon P on behalf of CIBIS Investigators. Survival and prognostic factors in heart failure during the CIBIS trial.Circulation 90:1–380, 1994.Google Scholar
  18. 18.
    Suwa M, Otake Y, Moriguchi A, Ito T, Hirota Y, Kawamura K, et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to β-blocker therapy in patients with dilated cardiomyopathy.Am Heart J 133: 353–358, 1997.PubMedCrossRefGoogle Scholar
  19. 19.
    Fukuoka S, Hayashida K, Hirose Y, Shimotsu Y, Ishida Y, Kakuchi H, et al. Use of iodine-123 metaiodobenzyl-guanidine myocardial imaging to predict the effectiveness of β-blocker therapy in patients with dilated cardiomyopathy.Eur J Nucl Med 24: 523–529, 1997.PubMedGoogle Scholar
  20. 20.
    Dec GW, Fuster V. Idiopathic dilated cardiomyopathy.N Engl J Med 331: 1564–1575, 1994.PubMedCrossRefGoogle Scholar
  21. 21.
    Scheuer J. Metabolic factors in myocardial failure.Circulation 87 (Suppl 7): 54–5719, 1993.Google Scholar
  22. 22.
    Hock A, Freundlieb C, Vyska K, Losse B, Erbel R, Ludwig E. Myocardial imaging and metabolic studies with (17-123 I) iodoheptadecanoic acid in patients with idiopathic congestive cardiomyopathy.J Nucl Med 24: 22–28, 1983.PubMedGoogle Scholar
  23. 23.
    Ugolini V, Hansen CL, Kulkami PV. Abnormal myocardial fatty acid metabolism in dilated cardiomyopathy detected by iodine-123 phenylpentadecanoic acid and tomographic imaging.Am J Cardiol 62: 923–928, 1988.PubMedCrossRefGoogle Scholar
  24. 24.
    Mody FV, Brunken RC, Stevenson LW, Nienaber CA, Phelps ME, Schelbert HR. Differentiating cardiomyopathy of coronary artery disease from nonischemic dilated cardiomyopathy utilizing positron emission tomography.J Am Coll Cardiol 17: 373–383, 1991.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1998

Authors and Affiliations

  • Keiichiro Yoshinaga
    • 1
  • Minoru Tahara
    • 1
  • Hiroyuki Torii
    • 1
  • Koichi Kihara
    • 2
  1. 1.Department of CardiologyKagoshima City Medical Association HospitalKagoshimaJapan
  2. 2.First Department of Internal Medicine, Faculty of MedicineKagoshima UniversityJapan

Personalised recommendations